AME vs ROP: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

AME and ROP are similarly sized, but ROP trades noticeably cheaper on forward earnings (19.08x vs 24.66x): the market is paying up for AME's profile and pricing ROP more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.

AME vs ROP: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAMEROPWhat it tells you
Market cap$54.39B$46.43BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E24.6619.08Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E33.4518.55Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.970.66Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range67% of range81% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.652.42How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: ROP is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how AME and ROP affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AME and ROP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AME and ROP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AMETEK (AME) do?

AMETEK is a Berwyn, Pennsylvania manufacturer of electronic instruments and electromechanical devices, founded in 1930 and employing roughly 22,500 people. It runs two segments. The Electronic Instruments Group (EIG) builds analytical, test and measurement, process and aerospace instrumentation, including power quality monitors, materials analysis systems and cockpit sensors. The Electromechanical Group (EMG) makes engineered electrical connectors and interconnects, precision motion components, thermal management products and, since the Paragon Medical acquisition, contract-manufactured medical instruments and implantable components. The common thread is niche leadership: AMETEK deliberately targets small, differentiated product categories where it can hold a top position and price for engineering content rather than compete on volume.

Full AME guide

What does Roper Technologies (ROP) do?

Roper Technologies has spent the past decade reinventing itself from an industrial tools and equipment maker into a diversified holding company whose center of gravity is vertical-market software. It operates through three segments: Application Software (businesses like Deltek for government contractors, Vertafore in insurance, Aderant for law firms, Frontline in K-12 education, and Clinisys in diagnostics), Network Software (network-effect platforms such as DAT in freight and iPipeline in insurance), and Technology Enabled Products (Neptune water meters, Verathon and CIVCO in medical devices). More than half of total revenue is now recurring, coming from SaaS subscriptions, maintenance and transaction fees, and application plus network software together generate roughly three-quarters of revenue.

Full ROP guide

AME vs ROP: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • AME drivers: Record orders tied to AI infrastructure, aerospace and defense; The $5 billion Indicor instrumentation acquisition.
  • ROP drivers: Acquisition-driven compounding; Recurring, high-margin software mix.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. For ROP, sentiment is the most visible risk right now: ROP sits far below its 52-week high of about $519 and has de-rated to roughly 16x earnings, which shows how quickly the market can reprice a software compounder when growth or AI disruption worries rise.

AME or ROP: which should you pick?

Pick AME if you believe its drivers more; ROP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AME and ROP guides.

AME vs ROP: the full fundamentals

AME. As of October 16, 2026, AMETEK trades at a clear premium to the broader industrial group, with a trailing P/E near 36, a forward P/E near 26 and EV/EBITDA around 23.5. The premium reflects roughly 26 percent operating margins, steady free cash flow and a long record of accretive acquisitions rather than unusual top-line growth. The shares closed at $248.41 against a 52-week range of roughly $183 to $261 and an average analyst target near $282, with Q3 2026 results due November 3.

ROP. Roper trades near 16x both trailing and forward earnings and about 15x EV/EBITDA, a sharp de-rating from the low-20s trailing multiple it carried earlier in 2026 and far below its longer-run median. Part of the low trailing figure comes from an unusually large Q2 2026 GAAP profit, so the forward multiple on about $24 of 2027 consensus EPS is the cleaner read. Fourteen analysts carry a mean target near $439, and Q3 results land on October 22, 2026 against a consensus of about $5.79 per share.

Headline figures (approximate, October 2026): AME shows revenue (ttm) ~$7.86B; Q2 2026 up ~15% YoY, operating margin ~26%, net income (ttm) ~$1.58B (~20% margin), q2 2026 sales / adj. eps ~$2.04B (+15%) / ~$2.09 vs ~$1.99 est.; ROP shows revenue (ttm) ~$8.3 billion (up ~8.5% YoY in Q2), q2 2026 revenue ~$2.11 billion, q2 2026 eps vs estimate $5.38 vs ~$5.29, gross / operating margin ~70% / ~28%.

The bottom line: AME vs ROP

AME and ROP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AME and ROP exposure against your real portfolio. It is not an investment adviser.

Wondering how AME or ROP fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AMETEK

Ask Walnut's AI anything about AME and see how it fits what you own.

FAQ

What is the difference between AME and ROP?

+

AMETEK is a Berwyn, Pennsylvania manufacturer of electronic instruments and electromechanical devices, founded in 1930 and employing roughly 22,500 people. Roper Technologies has spent the past decade reinventing itself from an industrial tools and equipment maker into a diversified holding company whose center of gravity is vertical-market software. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AME or ROP the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AME or ROP?

+

On forward P/E (as of November 2026), AME trades at 24.66x and ROP at 19.08x, so ROP is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AME and ROP?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AME vs ROP?

+

AME: Valuation is the most immediate risk: at roughly 36 times trailing and about 26 times forward earnings, with an EV/EBITDA near 23.5, the shares price in continued execution and leave limited room for a demand air pocket. The Indicor deal carries integration and leverage risk at a size AMETEK has not attempted before, and cost synergies of 10 to 12 percent are a target rather than a result. Roughly half of sales come from outside the United States, exposing results to currency, tariffs and global capital spending cycles, while short-cycle instrument orders can turn quickly if industrial demand cools. AI infrastructure and defense are currently strong contributors and would become concentration risks if either budget cycle reversed. Expectations into the November 3, 2026 report are elevated after four consecutive EPS beats and target increases from Morgan Stanley (to $275) and Citigroup (to $263) in October. Separately, AMETEK carries long-running environmental and toxic tort litigation related to groundwater contamination from a former subsidiary site in El Cajon, California, an ordinary-course legal exposure disclosed in its filings; no active securities-fraud class action was identified against the company as of August 2026. ROP: Sentiment is the most visible risk right now: ROP sits far below its 52-week high of about $519 and has de-rated to roughly 16x earnings, which shows how quickly the market can reprice a software compounder when growth or AI disruption worries rise. The model depends on continually acquiring good companies at sensible prices, and rising multiples for premium software assets can weigh on returns over time. Aggressive M&A has also lifted debt to about $11.3 billion against roughly $365 million of cash and left goodwill and intangibles as a large share of the balance sheet, creating impairment risk if acquired businesses underperform. The jump in Q2 2026 GAAP earnings flatters trailing ratios, so headline P/E and margin overstate the run-rate. AI could disrupt the switching costs and stickiness that protect its software niches. Finally, as a decentralized holding company spanning dozens of businesses, execution and integration risk is spread across many units and is harder for outsiders to monitor.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AME or ROP; figures are approximate and dated (as of November 2026). Verify current data before investing.